The immuno-oncology therapy developer, which is backed by Novo, Sanofi, EMS and Seattle Genetics, has raised $77m in venture funding.
US-based immunotherapy developer Unum Therapeutics has filed to raise up to $86.3m in an initial public offering that will allow subsidiaries of pharmaceutical companies Novo, Sanofi, EMS and Seattle Genetics to exit.
Unum is developing immuno-oncology drugs that will fight cancer by triggering reactions in a patient’s immune system. Its lead program is a cell therapy based on its antibody-coupled T cell receptor technology that will work in tandem with antibiotics.
The proceeds from the offering will fund the…
